MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company dedicated to transforming care for fluid overload patients, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.
Related Questions
What were the revenue and earnings figures for Q2 2025, and how do they compare to analyst expectations?
Did the company provide any guidance for Q3 2025 or full-year 2025, and how does it stack up against consensus forecasts?
What were the key drivers behind any revenue growth or decline (e.g., product sales, geographic expansion, regulatory approvals)?
Are there any notable changes in operating expenses, R&D spend, or SG&A that could affect profitability margins?
How does the cash position and burn rate look, and when will the company need additional financing, if any?
Did the company announce any major partnership, acquisition, or commercialization milestone that could impact future growth?
How does Nuwellis' valuation metrics (P/E, EV/EBITDA, price-to-sales) compare to peers in the medical technology sector?
Are there any insider transactions or recent changes in institutional ownership following the release?
What is the market's reaction to the earnings surprise (if any), and what are the short‑term price targets from analysts?
What is the status of the company's FDA or other regulatory submissions and expected approval timelines?